



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Demo Report

Report Issued 03/30/2020 13:03
Last Report Issued 07/18/2008 08:03

88888
Clinical Example Report
Attn: Example Reports
200 Welsh Road
Horsham, PA 19044

Patient Name 3260SP-POS
Patient ID 3260SP-POS
Chain 1
Age Not Given DOB Not Given
Gender Not Given
Workorder 08002159
Received 07/17/2008 07:46

Sample ID 08002159-001
Matrix Serum or Plasma
Patient Name 3260SP-POS
Patient ID 3260SP-POS
Container Type Clear vial

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes None Entered

Table with 5 columns: Analysis and Comments, Result, Units, Reporting Limit, Notes

3260SP Oxazepam, Serum/Plasma

Analysis by High Performance Liquid Chromatography/
Tandem Mass Spectrometry (LC-MS/MS)

Table row for Oxazepam: Result 5000, Units ng/mL, Reporting Limit 20, Notes ELEVATED

Synonym(s): Serax®

When used as a drug, the therapeutic plasma
concentration: 200 -1400 ng/mL.
Potentially toxic greater than 2000 ng/mL.

As a metabolite of Diazepam, low concentrations may be
observed. In one study, following chronic daily doses
of about 70 mg of Diazepam, the steady-state serum
concentrations were 50 - 400 ng Oxazepam/mL.

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US
Food and Drug Administration.